UNCY
HealthcareUnicycive Therapeutics, Inc.
$5.52
$-0.28 (-4.83%)
Jan 5, 2026
Price History (1Y)
Analysis
Unicycive Therapeutics, Inc. is a biotechnology company operating in the healthcare sector. With a market capitalization of $118.63 million and 22 employees, it falls within the smaller scale for companies in this industry. The company's financial health is marked by significant net losses, with a net income of -$33,412,000 over the trailing twelve months. This has resulted in unprofitable margins across all fronts, including gross margin at 0.0%, operating margin at 0.0%, and profit margin at 0.0%. Returns on equity and assets are also negative, standing at -102.3% and -44.2%, respectively. The balance sheet shows a cash position of $42.70 million against debt of $265,000, indicating a relatively strong liquidity position. Unicycive Therapeutics' valuation is characterized by a forward P/E ratio of 0.93, which suggests the market has placed significant pressure on the company's share price. The price to book ratio stands at 3.07, while the EV/EBITDA ratio is -2.61.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About Unicycive Therapeutics, Inc.
Unicycive Therapeutics, Inc., a clinical-stage biotechnology company, identifies, develops, and commercializes therapies to address unmet medical needs in the United States. Its drug candidates include UNI 494, a pro-drug of Nicorandil that is being developed as a treatment for acute kidney injury; and Renazorb RZB 012 for the treatment of hyperphosphatemia in patients with chronic kidney disease. The company also evaluates licensing of technologies and drugs for orphan diseases, other renal, liver, and other metabolic diseases affecting fibrosis and inflammation. Unicycive Therapeutics, Inc. has license agreements with Shilpa Medicare Ltd to develop and commercialize oxylanthanum carbonate; Sphaera Pharma Pte. Ltd.; Syneos Health LLC to develop of UNI-494; Inotiv for preclinical trial and related services for oxylanthanum carbonate and UNI-494; Lee's Pharmaceutical (HK) Limited; and Lotus International Pte Ltd for the development, registration filing, and approval for oxylanthanum carbonate. The company was incorporated in 2016 and is based in Los Altos, California.
Visit website →Key Statistics
- Market Cap
- $118.63M
- P/E Ratio
- N/A
- 52-Week High
- $11.00
- 52-Week Low
- $3.71
- Avg Volume
- 413.19K
- Beta
- 1.84
Company Info
- Industry
- Biotechnology
- Exchange
- NCM
- Country
- United States
- Employees
- 22